Thanks for the links regarding Anavex; chromatin.
This abstract excerpt from your link provides the appropriate focus:
Epigenetic mechanisms are fundamental key features of developing cells connecting developmental regulatory factors to chromatin modification.
The real story, I believe, will not be Anavex's chromatin modulation, per se; rather it will be the suppression of adverse epigenetics
. Now, the Anavex epigenetics factor will come into consideration and play.
In classical genetics (which I taught my talented advanced placement biology students, and everyone learned in a biology course), DNA is a sequence of nucleotides, A's and T's, G's and C's. Those precise sequences form the genetic code, which, by translation directs the ribosomes to precisely connect amino acids in strands called peptides. In the endoplasmic reticula the peptides are both connected and precisely folded, producing proteins, most often enzyme proteins that control virtually all of the cell's chemical reactions.
If the peptide/proteins get misfolded, bad chemistry happens. Blarcamesine tends to prevent this.
But often, "epigenetics" are involved, where poorly functioning proteins are formed, because of translation errors involving chromatin malfunctions. New, unintended adverse reactions occur. Many diseases are epigenetic, including many cancers. Keep epigenetic anomalies from developing and the health of an organism is greatly improved.
Let's watch to see how epigenetics, involving chromatin modulation, now enter the Anavex discussions. Really big. A gigantic new medical landscape for the company.